Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
IDEXX Laboratories to Participate in Morgan Stanley 24th Annual Global Healthcare Conference
IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced that Mike Erickson, President and Chief Executive Officer, and Andrew Emerson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 24th...
Business Wire
More News
Idexx Laboratories (IDXX) is a Top-Ranked Growth Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Here's Why Idexx Laboratories (IDXX) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
Is it a Prudent Move to Retain IDEXX Stock in Your Portfolio Now?
IDXX's CAG diagnostics and cloud software growth support recurring revenues, while FX exposure and distributor inventory swings remain key risks.
Zacks
IDXX Raises 2026 EPS Outlook as Diagnostic Growth and Margins Improve
IDEXX raises its 2026 EPS outlook as recurring diagnostics growth, wider margins and international expansion offset softer U.S. veterinary traffic.
Zacks
Is IDXX Worth Buying as Growth Strength Meets a Premium Valuation?
IDEXX pairs resilient diagnostics growth, margin gains and expanding innovation with a premium valuation that supports a hold-or-wait stance.
Zacks
Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
Here is Why Growth Investors Should Buy Idexx (IDXX) Now
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.
Zacks
IDXX Q2 Earnings & Revenues Beat, '26 EPS View Up, Stock Up in Pre-Market
IDEXX Laboratories beats Q2 estimates, expands margins and raises its 2026 EPS outlook as diagnostics demand and adoption fuel growth.
Zacks
Why Is IDEXX Laboratories Stock Gaining Tuesday?
IDEXX Laboratories (IDXX) stock rose after reporting Q2 earnings of $4.27/share and $1.22B in revenue, beating Wall Street estimates.read more...
Benzinga

Advertisement|Remove ads.